Subject Preference for Scalp Psoriasis Treatment

Status Completed

Clinical Trial Summary

The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress. Topical agents remain the mainstay of treatment for scalp psoriasis. However, they are not always ideal because they might be inconvenient and messy to use, stain or damage hair. The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a short-contact therapy in order to improve the chances of it being effective and reduce the potential for traditional side-effects. The objective of this study is to compare subject's overall preference between Clobetasol propionate shampoo 0.05% and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis.

Clinical Trial Description

This study will be a multi-centre, investigator blinded, randomized, cross-over, intra-individual comparison in three parallel groups. In each parallel group, Clobetasol propionate shampoo, 0.05% will be compared to one of the three chosen competitors, following a cross-over design. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00438399
Study type	Interventional
Source	Galderma R&D
Contact
Status	Completed
Phase	Phase 3
Start date	February 2007
Completion date	February 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00400725` - Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis	Phase 3
Completed	`NCT01195831` - Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis	Phase 3
Completed	`NCT03880357` - To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis	Phase 1
Completed	`NCT03331523` - To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis	Phase 3
Completed	`NCT04801433` - Evaluate the Efficacy and Safety of Boroda Supramolecular Active Zinc in the Treatment of Scalp Psoriasis	N/A
Completed	`NCT01120223` - Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis	Phase 2
Completed	`NCT03897088` - Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis	Phase 3
Completed	`NCT02932462` - Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis	Phase 3
Completed	`NCT02933866` - Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis	Phase 3
Completed	`NCT05872256` - A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis	Phase 4
Active, not recruiting	`NCT05272150` - Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis	Phase 3
Completed	`NCT02933502` - Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product	Phase 2
Completed	`NCT01052467` - Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)	N/A
Completed	`NCT04243486` - A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis	Phase 2
Recruiting	`NCT02749656` - Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis	Phase 3
Completed	`NCT02078297` - IL-17 Role in Variants of Psoriasis	N/A
Completed	`NCT05028582` - Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)	Phase 3
Completed	`NCT01914627` - Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis	Phase 2
Not yet recruiting	`NCT01558310` - A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis	Phase 4
Recruiting	`NCT05969223` - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis	Phase 4